Espen Molden

10.4k total citations
184 papers, 3.9k citations indexed

About

Espen Molden is a scholar working on Pharmacology, Psychiatry and Mental health and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Espen Molden has authored 184 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Pharmacology, 83 papers in Psychiatry and Mental health and 47 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Espen Molden's work include Pharmacogenetics and Drug Metabolism (95 papers), Schizophrenia research and treatment (63 papers) and Pharmacological Effects and Toxicity Studies (36 papers). Espen Molden is often cited by papers focused on Pharmacogenetics and Drug Metabolism (95 papers), Schizophrenia research and treatment (63 papers) and Pharmacological Effects and Toxicity Studies (36 papers). Espen Molden collaborates with scholars based in Norway, Sweden and Serbia. Espen Molden's co-authors include Tore Haslemo, Monica Hermann, Magnus Ingelman‐Sundberg, Marin M. Jukić, Helge Refsum, Robert L. Smith, Ida Rudberg, Hege Christensen, H. Refsum and Anders Åsberg and has published in prestigious journals such as PLoS ONE, American Journal of Psychiatry and Biological Psychiatry.

In The Last Decade

Espen Molden

176 papers receiving 3.8k citations

Peers

Espen Molden
Per Damkier Denmark
Jules Desmeules Switzerland
Gail D. Anderson United States
L. F. Gram Denmark
Larry Ereshefsky United States
Bob Wilffert Netherlands
Adrián LLerena Spain
Staffan Hägg Sweden
C. Michael Stein United States
Jacques Turgeon Canada
Per Damkier Denmark
Espen Molden
Citations per year, relative to Espen Molden Espen Molden (= 1×) peers Per Damkier

Countries citing papers authored by Espen Molden

Since Specialization
Citations

This map shows the geographic impact of Espen Molden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Espen Molden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Espen Molden more than expected).

Fields of papers citing papers by Espen Molden

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Espen Molden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Espen Molden. The network helps show where Espen Molden may publish in the future.

Co-authorship network of co-authors of Espen Molden

This figure shows the co-authorship network connecting the top 25 collaborators of Espen Molden. A scholar is included among the top collaborators of Espen Molden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Espen Molden. Espen Molden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Johansson, Inger, Yitian Zhou, Maaike van der Lee, et al.. (2025). Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account. Clinical Pharmacology & Therapeutics. 118(1). 218–231.
3.
Schultz, Nina Haagenrud, et al.. (2024). Apixaban removal during emergency surgery for type A acute aortic dissection: a prospective cohort study. International Journal of Surgery. 110(12). 7782–7790. 1 indexed citations
4.
Smith, Robert L., et al.. (2024). Effect of the NFIB rs28379954 T>C polymorphism on CYP2D6‐catalyzed metabolism of solanidine. Clinical and Translational Science. 17(2). e13743–e13743. 5 indexed citations
5.
Molden, Espen, et al.. (2024). Pharmacogenetic Variants and Plasma Concentrations of Antiseizure Drugs. JAMA Network Open. 7(8). e2425593–e2425593. 2 indexed citations
6.
Schultz, Nina Haagenrud, et al.. (2024). Does in vitro hemolysis affect measurements of plasma apixaban concentration by UPLC‐MS and anti‐Xa assay?. International Journal of Laboratory Hematology. 46(5). 946–952. 1 indexed citations
7.
Hole, Kristine, et al.. (2023). Effect of CYP2D6 genotype on duloxetine serum concentration. Basic & Clinical Pharmacology & Toxicology. 134(1). 186–192. 5 indexed citations
8.
Cuevas, Carlos De las, Emílio J. Sanz, Christoph U. Correll, et al.. (2023). Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK. Schizophrenia Research. 268. 175–188. 10 indexed citations
9.
Størset, Elisabet, et al.. (2023). Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites—a study in 839 patients with known CYP2D6 genotype. European Journal of Clinical Pharmacology. 79(4). 523–531. 15 indexed citations
10.
Smith, Robert L., et al.. (2023). Evidence for solanidine as a dietary CYP2D6 biomarker: Significant correlation with risperidone metabolism. British Journal of Clinical Pharmacology. 90(3). 740–747. 12 indexed citations
11.
Mathiesen, Liv, et al.. (2023). Implementation of pharmacogenetic testing in medication reviews in a hospital setting. British Journal of Clinical Pharmacology. 89(10). 3116–3125. 4 indexed citations
12.
Schultz, Nina Haagenrud, et al.. (2022). In Vitro Apixaban Removal By CytoSorb Whole Blood Adsorber: An Experimental Study. Journal of Cardiothoracic and Vascular Anesthesia. 36(6). 1636–1644. 17 indexed citations
13.
Schoretsanitis, Georgios, Robert L. Smith, Espen Molden, et al.. (2021). European Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed. Journal of Clinical Psychopharmacology. 41(2). 140–147. 19 indexed citations
14.
15.
Mowé, Morten, et al.. (2020). Effect of medicines management versus standard care on readmissions in multimorbid patients: a randomised controlled trial. BMJ Open. 10(12). e041558–e041558. 21 indexed citations
16.
Steen, Nils Eiel, Kåre I. Birkeland, Ingrid Dieset, et al.. (2019). Adipokine levels are associated with insulin resistance in antipsychotics users independently of BMI. Psychoneuroendocrinology. 103. 87–95. 19 indexed citations
17.
Mowé, Morten, et al.. (2019). Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward. PLoS ONE. 14(7). e0220071–e0220071. 22 indexed citations
18.
Steen, Nils Eiel, Kåre I. Birkeland, Ingrid Dieset, et al.. (2018). Free thyroxine and thyroid-stimulating hormone in severe mental disorders: A naturalistic study with focus on antipsychotic medication. Journal of Psychiatric Research. 106. 74–81. 35 indexed citations
19.
Christensen, Hege, et al.. (2010). CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity. Xenobiotica. 41(1). 1–5. 12 indexed citations
20.
Molden, Espen & Olav Spigset. (2007). Frukt og bær – interaksjoner med legemidler. Tidsskrift for Den Norske Laegeforening.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Per Damkier Breakdown of academic impact, for papers by Jules Desmeules Breakdown of academic impact, for papers by Gail D. Anderson Breakdown of academic impact, for papers by L. F. Gram Breakdown of academic impact, for papers by Larry Ereshefsky Breakdown of academic impact, for papers by Bob Wilffert Breakdown of academic impact, for papers by Adrián LLerena Breakdown of academic impact, for papers by Staffan Hägg Breakdown of academic impact, for papers by C. Michael Stein Breakdown of academic impact, for papers by Jacques Turgeon
Rankless by CCL
2026